trending Market Intelligence /marketintelligence/en/news-insights/trending/UDbfxVUQcnE-yPQ27S2LXQ2 content esgSubNav
In This List

Kino Biotech Q1 profit falls YOY

Blog

Capital Markets Activity Infographic: SPAC Volume Rises in Q3; Equity Issuance Drops but Remains Strong in Several Sectors

Blog

Asset Owner Perspectives on Climate Change Measurement, Management, and Reporting in Australia

Blog

How Financial Institutions are Managing Exposure to U.S. Municipals

Blog

Insight Weekly: Global stock performance; hydrogen pilot projects; Powell's Fed future unsure


Kino Biotech Q1 profit falls YOY

Kino Biotech Co. Ltd. said its first-quarter normalized net income amounted to 9 Taiwan cents per share, a decrease of 24.5% from 12 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$1.8 million, a decrease of 31.9% from NT$2.6 million in the prior-year period.

The normalized profit margin declined to 1.7% from 2.5% in the year-earlier period.

Total revenue increased on an annual basis to NT$106.2 million from NT$102.3 million, and total operating expenses increased 6.6% year over year to NT$105.6 million from NT$99.1 million.

Reported net income fell 29.1% from the prior-year period to NT$2.6 million, or 13 cents per share, from NT$3.7 million, or 17 cents per share.

As of May 15, US$1 was equivalent to NT$30.44.